钱军 . 骨髓增殖性肿瘤的分子诊断进展[J]. 诊断学理论与实践, 2020 , 19(02) : 104 -110 . DOI: 10.16150/j.1671-2870.2020.02.002
| [1] | Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues[M].. Revised 4th ed. Lyon: International Agency for Research on Cancer, 2017. |
| [2] | Baccarani M, Castagnetti F, Gugliotta G, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview[J]. Leukemia, 2019, 33(5):1173-1183. |
| [3] | Arun AK, Senthamizhselvi A, Mani S, et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients[J]. Int J Lab Hematol, 2017, 39(3):235-242. |
| [4] | Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia[J]. Br J Haematol, 2000, 109(3):635-637. |
| [5] | Soderquist CR, Ewalt MD, Czuchlewski DR, et al. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group[J]. Mod Pathol, 2018, 31(5):690-704. |
| [6] | Martin-Cabrera P, Haferlach C, Kern W, et al. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance[J]. Br J Haematol, 2017, 176(1):135-139. |
| [7] | Pieri L, Spolverini A, Scappini B, et al. Concomitant occurrence of BCR-ABL and JAK2 V617F mutation[J]. Blood, 2011, 118(12):3445-3446. |
| [8] | Bader G, Dreiling B. Concurrent JAK2-positive myeloproliferative disorder and chronic myelogenous leukemia: A novel entity? A case report with review of the literature[J]. J Investig Med High Impact Case Rep, 2019, 7:2324709619832322. |
| [9] | Elliott MA, Tefferi A. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and mana-gement[J]. Am J Hematol, 2018, 93(4):578-587. |
| [10] | Szuber N, Tefferi A. Chronic neutrophilic leukemia: new science and new diagnostic criteria[J]. Blood Cancer J, 2018, 8(2):19. |
| [11] | Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia[J]. Blood, 2017, 129(6):704-714. |
| [12] | Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes[J]. J Allergy Clin Immunol, 2012, 130(3):607-612. |
| [13] | Cross NCP, Hoade Y, Tapper WJ, et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia[J]. Leukemia, 2019, 33(2):415-425. |
| [14] | Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2019, 94(1):133-143. |
| [15] | Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations 2000-2018[J]. BMC Cancer,2019, 19(1):590. |
| [16] | Delic S, Rose D, Kern W, et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera[J]. Br J Haematol, 2016, 175(3):419-426. |
| [17] | Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia[J]. Blood Adv, 2016, 1(1):21-30. |
| [18] | Senín A, Fernández-Rodríguez C, Bellosillo B, et al. Non-driver mutations in patients with JAK2 V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up[J]. Ann Hematol, 2018, 97(3):443-451. |
| [19] | Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms[J]. Blood, 2016, 127(3):325-332. |
| [20] | Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor(MPL) mutations in triple-negative essential thrombocythemia patients[J]. Blood, 2016, 127(3):333-342. |
| [21] | 鞠满凯, 付荣凤, 李慧媛, 等. 三阴性血小板增多症的患者特点及靶向基因测序分析[J]. 中国实验血液学杂志, 2018, 26(4):1137-1145. |
| [22] | Yoshimitsu M, Hachiman M, Uchida Y, et al. Essential thrombocytosis attributed to JAK2-T875N germline mutation[J]. Int J Hematol, 2019, 110(5):584-590. |
| [23] | Tefferi A, Nicolosi M, Mudireddy M, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-careggi MPN alliance study of 1,095 patients[J]. Am J Hematol, 2018, 93(3):348-355. |
| [24] | Caponetti GC, Bagg A. Genetic studies in the evaluation of myeloproliferative neoplasms[J]. Semin Hematol, 2019, 56(1):7-14. |
| [25] | Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons[J]. Leukemia, 2014, 28(7):1472-1477. |
| [26] | Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2018, 93(12):1551-1560. |
| [27] | Lin Y, Liu E, Sun Q, et al. The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms[J]. Am J Clin Pathol, 2015, 144(1):165-171. |
| [28] | Iurlo A, Gianelli U, Cattaneo D, et al. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version[J]. Am J Hematol, 2017, 92(4):E48-E51. |
/
| 〈 |
|
〉 |
